In general, most adverse effects are mild and transient with the most frequently reported being giddiness, diarrhea, headache, anorexia, gastric irritation, nausea, vomiting, abdominal pain usually occurring within the first month of treatment. Electrolyte imbalances including hypochloraemic alkalosis, hyponatraemia, hypokalaemia and hyperuricaemia. Signs of electrolyte imbalance include dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain and cramps, seizures, oliguria, hypotension, and gastrointestinal disturbances. Hypersensitivity reactions which include skin rashes, pulmonary edema, pneumonitis, cholestatic jaundice, pancreatitis and blood dyscrasias including thrombocytopenia and less frequently granulocytopenia, leucopenia, aplastic anemia and haemolytic anaemia have been reported. Serum potassium should be monitored in patients with a history of gout, who should continue to receive appropriate treatment. Other adverse effects include vertigo, fatigue, dizziness, muscle weakness, paraesthesia, syncope, visual impairment, hypotension, arrhythmia, torsade de pointes (potentially fatal), constipation, angioedema, urticaria and renal failure. The table as follows shows some undesirable effects which have been observed with indapamide during treatment. (See table.)
Click on icon to see table/diagram/image